Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L et al. Semin Oncol. 2015 Dec;42(6):788-800. doi: 10.1053/j.seminoncol.2015.09.024. Epub 2015 Sep 24.

Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults.
Guerard EJ et al. Clin Geriatr Med. 2016 Feb;32(1):191-205. doi: 10.1016/j.cger.2015.08.012. Epub 2015 Oct 9.

Multiple myeloma and physical activity: a scoping review.
Smith L et al. BMJ Open. 2015 Nov 27;5(11):e009576. doi: 10.1136/bmjopen-2015-009576.

Molecular mechanisms in multiple myeloma drug resistance.
Nikesitch N et al. J Clin Pathol. 2015 Nov 23. pii: jclinpath-2015-203414. doi: 10.1136/jclinpath-2015-203414. [Epub ahead of print].

Continued role for ASCT in multiple myeloma.
McCarthy PL et al. Lancet Oncol. 2015 Nov 16. pii: S1470-2045(15)00457-X. doi: 10.1016/S1470-2045(15)00457-X. [Epub ahead of print].

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update.
Cheson BD et al. Leuk Lymphoma. 2015 Nov 23:1-17. [Epub ahead of print].

Multiple myeloma: the quality of care is linked to geographical and organisational determinants. A study in a French registry.
Puyade M et al. Eur J Cancer Care (Engl). 2015 Nov 25. doi: 10.1111/ecc.12414. [Epub ahead of print].

Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study.
Arber A et al. Eur J Cancer Care (Engl). 2015 Nov 25. doi: 10.1111/ecc.12413. [Epub ahead of print].

The therapeutic potential of microbial proteasome inhibitors.
Momose I et al. Int Immunopharmacol. 2015 Nov 14. pii: S1567-5769(15)30183-1. doi: 10.1016/j.intimp.2015.11.013. [Epub ahead of print].

Centrosome amplification and clonal evolution in multiple myeloma: Short review.

Kryukova E et al. Crit Rev Oncol Hematol. 2015 Nov 2. pii: S1040-8428(15)30068-8. doi: 10.1016/j.critrevonc.2015.10.019. [Epub ahead of print].

The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation.
Munker R et al. Acta Haematol. 2015 Nov 21;135(3):146-155. [Epub ahead of print].

Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Wang Y et al. J Natl Cancer Inst. 2015 Nov 18;108(3). pii: djv342. doi: 10.1093/jnci/djv342. Print 2016 Mar.

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared to hospital administration: results of a prospective single-center study.
Lassalle A et al. Ann Oncol. 2015 Nov 16. pii: mdv563. [Epub ahead of print].

Herpes zoster and risk of cancer in the elderly US population.
Mahale P et al. Cancer Epidemiol Biomarkers Prev. 2015 Nov 17. pii: cebp.1033.2015. [Epub ahead of print].

Myeloma Today: Disease Definitions and Treatment Advances.
Rajkumar SV. Am J Hematol. 2015 Nov 13. doi: 10.1002/ajh.24236. [Epub ahead of print].

Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis.
Ailawadhi S et al. Cancer. 2015 Nov 13. doi: 10.1002/cncr.29771. [Epub ahead of print].

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy.
Suck G et al, Cancer Immunol Immunother. 2015 Nov 11. [Epub ahead of print].

Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Ray EL et al. Expert Rev Hematol. 2015 Nov 11. [Epub ahead of print].

SnapShot: Multiple Myeloma.
Braggio E et al. Cancer Cell. 2015 Nov 9;28(5):678-678.e1. doi: 10.1016/j.ccell.2015.10.014.

Role of Immune Therapies for Myeloma.
Rosenblatt J et al. J Natl Compr Canc Netw. 2015 Nov;13(11):1440-7.

Multiple Myeloma, Version 2.2016.
Anderson KC et al. J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

New Approaches to Molecular Imaging of Multiple Myeloma.
Vij R et al. J Nucl Med. 2015 Nov 5. pii: jnumed.115.163808. [Epub ahead of print].

The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia andmyeloma – a Swedish population-based study.
Mohammadi M et al. BMC Cancer. 2015 Nov 5;15:850. doi: 10.1186/s12885-015-1857-x.

Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma.
Usmani SZ et al. J Med Econ. 2015 Nov 17:1-16. [Epub ahead of print].

Interpretation of cytogenetic results in multiple myeloma for clinical practice.
Rajan AM et al. Blood Cancer J. 2015 Oct 30;5:e365. doi: 10.1038/bcj.2015.92.

Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features.
VanValkenburg ME et al. Cancer Causes Control. 2015 Nov 23. [Epub ahead of print]